Therapeutic proteins: developments, progress, challenges, and future perspectives
Abstract Proteins are considered magic molecules due to their enormous applications in the health sector. Over the past few decades, therapeutic proteins have emerged as a promising treatment option for various diseases, particularly cancer, cardiovascular disease, diabetes, and others. The formulation of protein-based therapies is a major area of research, however, a few factors still hinder the large-scale production of these therapeutic products, such as stability, heterogenicity, immunogenicity, high cost of production, etc. This review provides comprehensive information on various sources and production of therapeutic proteins. The review also summarizes the challenges currently faced by scientists while developing protein-based therapeutics, along with possible solutions. It can be concluded that these proteins can be used in combination with small molecular drugs to give synergistic benefits in the future..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
3 Biotech - 14(2024), 4 vom: 18. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Vimal [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© King Abdulaziz City for Science and Technology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13205-024-03958-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055199240 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055199240 | ||
| 003 | DE-627 | ||
| 005 | 20240410064655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13205-024-03958-z |2 doi | |
| 035 | |a (DE-627)SPR055199240 | ||
| 035 | |a (SPR)s13205-024-03958-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 333.7 |a 610 |q VZ |
| 084 | |a 58.30 |2 bkl | ||
| 100 | 1 | |a Kumar, Vimal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic proteins: developments, progress, challenges, and future perspectives |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © King Abdulaziz City for Science and Technology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Proteins are considered magic molecules due to their enormous applications in the health sector. Over the past few decades, therapeutic proteins have emerged as a promising treatment option for various diseases, particularly cancer, cardiovascular disease, diabetes, and others. The formulation of protein-based therapies is a major area of research, however, a few factors still hinder the large-scale production of these therapeutic products, such as stability, heterogenicity, immunogenicity, high cost of production, etc. This review provides comprehensive information on various sources and production of therapeutic proteins. The review also summarizes the challenges currently faced by scientists while developing protein-based therapeutics, along with possible solutions. It can be concluded that these proteins can be used in combination with small molecular drugs to give synergistic benefits in the future. | ||
| 650 | 4 | |a Therapeutic proteins |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sources |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Production |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Challenges |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Barwal, Arti |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Mir, Danish Shafi |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Vikas |e verfasserin |0 (orcid)0000-0001-7516-7807 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d Springer International Publishing, 2011 |g 14(2024), 4 vom: 18. März |w (DE-627)SPR030851394 |w (DE-600)2600522-0 |x 2190-5738 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:4 |g day:18 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13205-024-03958-z |m X:VERLAG |x 0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 58.30 |q VZ |
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 4 |b 18 |c 03 | ||